Please use this identifier to cite or link to this item: http://dspace.hmtu.edu.vn/handle/DHKTYTHD_123/381
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGotlib, Jason-
dc.date.accessioned2015-11-30T04:16:53Z-
dc.date.available2015-11-30T04:16:53Z-
dc.date.issued2013-
dc.identifier.urihttp://220.231.117.85:8000/handle/DHKTYTHD_123/381-
dc.description.abstractThe discovery of the JAK2 V617F mutation in the classic BCR-ABL1–negative myeloproliferative neoplasms in 2005 catalyzed a burst of research efforts that have culminated in substantial dividends for patients. Beyond JAK2 V617F, a more detailed picture of the pathobiologic basis for activated JAK-STAT signaling has emerged. In some patients with myelofibrosis (MF), next-generation sequencing technologies have revealed a complex clonal architecture affecting both genetic and epigenetic regulators of cell growth and differentiation. Although these bench-top findings have informed the clinical development of JAK inhibitors in MF, they have also provided scientific context for some of their limitations. The JAK1/JAK2 inhibitor ruxolitinib is approved for treatment of MF in North America and Europe and other lead JAK inhibitors discussed herein (fedratinib [SAR302503], momelotinib [CYT387], and pacritinib [SB1518]), have entered advanced phases of trial investigation. Uniformly, these agents share the ability to reduce spleen size and symptom burden. A major challenge for practitioners is how to optimize dosing of these agents to secure clinically relevant and durable benefits while minimizing myelosuppression. Suboptimal responses have spurred a “return to the bench” to characterize the basis for disease persistence and to inform new avenues of drug therapy.vi
dc.language.isoenvi
dc.publisherAmerican Society of Hematologyvi
dc.titleJAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedsidevi
dc.typeArticlevi
Appears in CollectionsHuyết học = Hematology

Files in This Item:
File Description SizeFormat 
Hematology-2013-Gotlib-529-37.pdf
  Restricted Access
1.98 MBAdobe PDFThumbnail
 Request Item


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.